Rational Combinations with Magrolimab in Hematologic Malignancies

Time: 8:30 am
day: Day One

Details:

• Demonstrating robust preclinical programs to create a rational therapeutic design and combination strategy
• Clinical efficacy of magrolimab in hematologic malignancies
• Share safety considerations of targeting CD47 and the toxicity profile seen in the clinic

Speakers: